171 related articles for article (PubMed ID: 36921916)
1. Frailty in Patients with Chronic Graft-versus-Host Disease.
Rashid N; Arora M; Jurdi NE; Onstad L; Pidala JA; Flowers ME; Lee SJ
Transplant Cell Ther; 2023 Jun; 29(6):367-374. PubMed ID: 36921916
[TBL] [Abstract][Full Text] [Related]
2. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Sung AD; Koll T; Gier SH; Racioppi A; White G; Lew M; Free M; Agarwal P; Bohannon LM; Johnson EJ; Selvan B; Babushok DV; Frey NV; Gill SI; Hexner EO; Martin M; Perl AE; Pratz KW; Luger SM; Chao NJ; Fisher AL; Stadtmauer EA; Porter DL; Loren AW; Bhatt VR; Gimotty PA; McCurdy SR
Transplant Cell Ther; 2024 Apr; 30(4):415.e1-415.e16. PubMed ID: 38242440
[TBL] [Abstract][Full Text] [Related]
3. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
5. Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study.
Arora M; Sun CL; Ness KK; Teh JB; Wu J; Francisco L; Armenian SH; Schad A; Namdar G; Bosworth A; Kuo L; Weisdorf DJ; Forman SJ; Bhatia S
JAMA Oncol; 2016 Oct; 2(10):1277-1286. PubMed ID: 27254472
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
7. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
[TBL] [Abstract][Full Text] [Related]
8. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
9. Association of Prediagnostic Frailty, Change in Frailty Status, and Mortality After Cancer Diagnosis in the Women's Health Initiative.
Cespedes Feliciano EM; Hohensee C; Rosko AE; Anderson GL; Paskett ED; Zaslavsky O; Wallace RB; Caan BJ
JAMA Netw Open; 2020 Sep; 3(9):e2016747. PubMed ID: 32926116
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
11. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
12. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
DeFilipp Z; Alousi AM; Pidala JA; Carpenter PA; Onstad LE; Arai S; Arora M; Cutler CS; Flowers MED; Kitko CL; Chen GL; Lee SJ; Hamilton BK
Blood Adv; 2021 Oct; 5(20):4278-4284. PubMed ID: 34521116
[TBL] [Abstract][Full Text] [Related]
13. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
[TBL] [Abstract][Full Text] [Related]
14. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
15. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of pre-transplant frailty and mental distress in hematopoietic cell transplantation and association with clinical outcomes.
Singh S; Cao Q; Demorest C; He F; Kramer A; Holtan S; Juckett M; Ramesh V; Arora M; Maakaron J; Weisdorf D; Jurdi NE
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38838780
[TBL] [Abstract][Full Text] [Related]
17. Impact of Center Volume on Chronic Graft Versus Host Disease in Patients With Allogeneic Stem Cell Transplantation.
Shimomura Y; Kitamura T; Murata M; Matsuo K; Ito Y; Ichinohe T; Hashii Y; Goto H; Kato K; Ishimaru F; Sato A; Onizuka M; Yanagisawa A; Ohbiki M; Tabuchi K; Atsuta Y; Fukuda T; Kanda J; Terakura S
Transplant Cell Ther; 2024 Mar; 30(3):326.e1-326.e14. PubMed ID: 38218451
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease.
Zhao AT; Pirsl F; Steinberg SM; Holtzman NG; Schulz E; Mina A; Mays JW; Cowen EW; Comis LE; Joe GO; Yanovski JA; Pavletic SZ
Bone Marrow Transplant; 2023 Dec; 58(12):1377-1383. PubMed ID: 37684526
[TBL] [Abstract][Full Text] [Related]
20. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.
DeFilipp Z; Kim HT; Yang Z; Noonan J; Blazar BR; Lee SJ; Pavletic SZ; Cutler C
Blood Adv; 2022 Dec; 6(24):6263-6270. PubMed ID: 36083121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
